Download MendeleyGenetic and chemical validation of Plasmodium falciparum aminopeptidase Pf A-M17 as a drug target in the hemoglobin digestion pathway.
Edgar, R.C.S., Siddiqui, G., Hjerrild, K., Malcolm, T.R., Vinh, N.B., Webb, C.T., Holmes, C., MacRaild, C.A., Chernih, H.C., Suen, W.W., Counihan, N.A., Creek, D.J., Scammells, P.J., McGowan, S., de Koning-Ward, T.F.(2022) Elife 11
- PubMed: 36097817 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.7554/eLife.80813
- Primary Citation Related Structures:
7RIE - PubMed Abstract:
Plasmodium falciparum, the causative agent of malaria, remains a global health threat as parasites continue to develop resistance to antimalarial drugs used throughout the world. Accordingly, drugs with novel modes of action are desperately required to combat malaria. P. falciparum parasites infect human red blood cells where they digest the host's main protein constituent, hemoglobin. Leucine aminopeptidase Pf A-M17 is one of several aminopeptidases that have been implicated in the last step of this digestive pathway. Here, we use both reverse genetics and a compound specifically designed to inhibit the activity of Pf A-M17 to show that Pf A-M17 is essential for P. falciparum survival as it provides parasites with free amino acids for growth, many of which are highly likely to originate from hemoglobin. We further show that loss of Pf A-M17 results in parasites exhibiting multiple digestive vacuoles at the trophozoite stage. In contrast to other hemoglobin-degrading proteases that have overlapping redundant functions, we validate Pf A-M17 as a potential novel drug target.
- School of Medicine, Deakin University, Geelong, Australia.
Organizational Affiliation:
